Essex Bio-Technology Limited disclosed that on 29 June 2026 it repurchased 10,000 ordinary shares on the Hong Kong Stock Exchange at a price of HKD 2.71 per share, for a total consideration of HKD 27,100.

Following the transaction: • Issued shares (excluding treasury shares) decreased to 566.27 million, down 0.00177%. • Treasury shares rose to 0.73 million. • Total issued shares remained at 567.01 million.

The buyback forms part of a mandate approved on 26 May 2026 authorising the company to repurchase up to 56.70 million shares. To date, 0.73 million shares—equivalent to 0.13% of the share base at mandate approval—have been repurchased, leaving capacity for a further 55.97 million shares.

In line with Hong Kong listing rules, Essex Bio-Tech is subject to a 30-day moratorium—through 29 July 2026—on issuing new shares or disposing of treasury shares following this repurchase. The company confirmed that the transaction complied with all regulatory requirements and its board authorisation.